At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 06-05 16:00:00 EDT
0.7300
-0.0700
-8.75%
盘后0.7300
+0.00000.00%
19:22 EDT
High0.8000Low0.7200Vol306.37K
Open0.8000D1 Closing0.8000Amplitude10.00%
Mkt Cap23.07MTradable Cap19.90MTotal Shares31.60M
T/O230.11KT/O Rate1.12%Tradable Shares27.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Announces CFO Transition to Internal Successor
TIPRANKS  ·  06-06 05:19
Longeveron Announces CFO Transition to Internal Successor
BRIEF-Longeveron - On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing
Reuters  ·  06-06 04:35
BRIEF-Longeveron - On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing
Longeveron - on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing
THOMSON REUTERS  ·  06-06 04:24
Longeveron - on June 1, Lisa Locklear to Step Down as CFO Effective July 10, 2026 - SEC Filing
Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing
THOMSON REUTERS  ·  06-06 04:24
Longeveron - Anticipates Marie Washburn to Be Elevated to CFO Pending Final Contract - SEC Filing
Longeveron to present at BIO International Convention 2026
Reuters  ·  06-04 21:15
Longeveron to present at BIO International Convention 2026
Longeveron shifts to capital-light model, targets licensing partners for laromestrocel
Reuters  ·  05-21
Longeveron shifts to capital-light model, targets licensing partners for laromestrocel
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
THOMSON REUTERS  ·  05-21
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Benzinga  ·  05-14
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Longeveron Q1 revenue rises, beats analyst estimates
Reuters  ·  05-14
Longeveron Q1 revenue rises, beats analyst estimates
BRIEF-Longeveron Q1 EPS USD -0.19
Reuters  ·  05-14
BRIEF-Longeveron Q1 EPS USD -0.19
Longeveron Q1 Revenue USD 378 Thousand
THOMSON REUTERS  ·  05-14
Longeveron Q1 Revenue USD 378 Thousand
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
GlobeNewswire  ·  05-14
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000
Reuters  ·  05-14
Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000
Longeveron reports DMC approval for laromestrocel study to continue as designed
TIPRANKS  ·  05-12
Longeveron reports DMC approval for laromestrocel study to continue as designed
Longeveron Cut to Hold From Buy by Maxim Group
Dow Jones  ·  05-12
Longeveron Cut to Hold From Buy by Maxim Group
Longeveron downgraded to Hold from Buy at Maxim
TIPRANKS  ·  05-11
Longeveron downgraded to Hold from Buy at Maxim
Longeveron DMC clears Phase 2b HLHS stem cell trial to complete
Reuters  ·  05-11
Longeveron DMC clears Phase 2b HLHS stem cell trial to complete
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  05-11
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026
THOMSON REUTERS  ·  05-11
Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026
Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion
THOMSON REUTERS  ·  05-11
Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--